LGMD2E/R4 (SGCB, Beta-Sarcoglycan): What a 23andMe Limb-Girdle Muscular Dystrophy Carrier Result Really Means, and the Investigational SRP-9003 Gene Therapy

LGMD2E/R4 (SGCB, Beta-Sarcoglycan): What a 23andMe Limb-Girdle Muscular Dystrophy Carrier Result Really Means, and the Investigational SRP-9003 Gene Therapy

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: A 23andMe carrier line for limb-girdle muscular dystrophy type 2E (LGMD2E) is not a diagnosis. The condition is autosomal recessive, so a carrier is healthy and stays healthy. It is caused by two broken copies of the SGCB gene, which makes beta-sarcoglycan, a protein that protects muscle fibers. Risk to a future child rises only if both partners carry a variant. The 23andMe test reads just one founder change common in Amish families, so a negative result is only partial reassurance. And a gene therapy, SRP-9003, reported promising Phase 1/2 results in 2024, though it remains investigational and unapproved.

What you’ll learn:

• What being an SGCB carrier does and does not mean for your own health
• The real per-pregnancy odds if you and your partner are both carriers
• How a 23andMe result differs from what a neurologist or genetic counselor orders
• Where the widely covered gene-therapy headlines actually stand today

How LGMD2E is inherited: the SGCB gene and the muscle-fiber shield

Limb-girdle muscular dystrophy type 2E, now also called LGMD R4, comes from changes in a gene named SGCB. This gene sits on chromosome 4 and makes a protein called beta-sarcoglycan. Beta-sarcoglycan is one part of a larger support structure inside muscle cells.

Think of a muscle fiber like a tent. The dystrophin-glycoprotein complex is the set of ropes and stakes that anchors the fabric to the ground. Beta-sarcoglycan is one stake in that system. It helps connect the muscle cell’s inner skeleton to the tissue outside, which strengthens fibers during each contraction.

The sarcoglycan proteins work as a team, so they depend on each other. Early research showed that losing beta-sarcoglycan makes the whole sarcoglycan group fall apart. When those stakes pull loose, the muscle-cell membrane becomes fragile and tears with use. Over time, this leads to progressive muscle damage and the limb-girdle weakness pattern around the shoulders and hips.

The inheritance is autosomal recessive. That means a person must inherit one broken SGCB copy from each parent to be affected. A carrier has one working copy and one broken copy, so a carrier stays healthy. The 23andMe test looks at one specific SGCB change, c.461C>G (also written p.Thr151Arg), a founder variant common in Old Order Amish families and read as a single genetic spot.

A simple Punnett-square rule follows. If two carriers have a child, three outcomes are possible per pregnancy:

• 25% chance the child is affected — inherits a broken SGCB copy from each parent
• 50% chance the child is a carrier — inherits one broken copy and one working copy, and stays healthy
• 25% chance the child inherits neither variant — two working copies

Because the direct-to-consumer test checks only one variant, its scope matters for how you read the result. If any of this feels overwhelming, a board-certified genetic counselor can walk you through your own numbers (find one at NSGC.org).

Section recap: LGMD2E is autosomal recessive; a carrier of one broken SGCB copy is healthy, and the 23andMe test reads only one founder variant.

What are the actual odds? Turning carrier status into real numbers

It helps to translate the genetics into plain numbers. LGMD2E overall is rare, but among the sarcoglycanopathies, beta-sarcoglycan disease is one of the more common forms in several populations. The specific c.461C>G founder variant is concentrated in Old Order Amish and Pennsylvania Dutch-descended communities, so it is far more common there and nearly absent in the general population.

Here is the key math for a carrier like our reader:

• Both partners carriers: 25% per pregnancy, or about 25 out of 100 pregnancies, that a child is affected
• Only one partner a carrier (other tests negative): practical risk to a child is very low, but not mathematically zero, because the single-variant home test misses many other SGCB changes

It is worth separating two very different situations:

• Carrier status means you are healthy; it only matters for family planning
• An affected diagnosis means two broken copies plus real muscle symptoms, a different medical picture

Being affected by SGCB disease is essentially fully penetrant, meaning two broken copies reliably cause disease. But the course varies widely. Some people show symptoms before age 8 and lose walking in their teens. Milder cases show weakness as teenagers and lose walking in their forties. A large European cohort confirmed this wide range in onset and severity, from a Duchenne-like course to milder later weakness. So phenotype and progression cannot be read off a carrier result, and a genetic counselor or neurologist can interpret your specific situation.

Section recap: If both partners carry a variant, the per-pregnancy risk is about 25 out of 100; carrier status alone is healthy and cannot predict severity.

Testing options: the 23andMe result versus what a clinic orders

The testing you receive depends on why you are testing. For someone with muscle symptoms, the clinical pathway usually moves through several steps:

• Step 1 — Creatine kinase (CK) blood test: an enzyme that leaks from damaged muscle and is usually very high in LGMD
• Step 2 — Molecular testing: typically a multi-gene neuromuscular sequencing panel or SGCB-focused testing
• Step 3 — Muscle biopsy with sarcoglycan staining: reserved for unclear cases and done at certified labs

This symptom-driven pathway usually starts with a neurologist and a genetics evaluation.

For family planning, the pathway is different. Carrier screening is ordered through an OB-GYN or genetic counselor, either as targeted founder-variant testing or as broad expanded carrier screening. A professional guideline recommends offering expanded carrier screening to all pregnant and preconception patients, not just ethnicity-based panels.

Now the crucial contrast. The 23andMe carrier report tests only the single SGCB founder variant, c.461C>G, as one genetic spot, and it is explicitly a carrier screen, not a diagnostic test. Regulators authorized these direct-to-consumer reports as carrier screens after the company showed high accuracy and user comprehension. Even so, the reports read pre-defined variants rather than sequencing the whole gene. So a home-test “variant not detected” result does not rule out the many other SGCB variants and is not a substitute for clinical screening.

Think of it like a metal detector set to find one specific coin. Finding that coin is meaningful, but not finding it does not mean the beach is empty. Also note that LGMD is not on standard US newborn screening panels, so it is found through symptom-driven evaluation or reproductive testing, not routine newborn screening. A genetic counselor can help you decide whether a fuller SGCB panel is worthwhile (NSGC.org).

Section recap: A 23andMe report reads one founder variant as a carrier screen; clinical testing (CK, sequencing panels, biopsy) is far more comprehensive.

Reading your result: carrier, affected, or a variant of uncertain significance

Families may hear one of three outcomes, and the differences matter:

• Carrier result: one pathogenic SGCB variant, almost always the c.461C>G founder change on the home test. The person is healthy, and the result matters only for reproductive planning. This is the situation most 23andMe users are in.
• Affected diagnosis: two pathogenic SGCB variants together with a confirmed limb-girdle myopathy. A neurologist establishes this using creatine kinase, molecular testing, and biopsy where needed. This is a clinical diagnosis, not something a carrier report can give.
• Variant of uncertain significance (VUS): a change whose meaning is not yet clear, which broad sequencing panels can turn up. Professional standards define five categories, from pathogenic to benign, with VUS in the middle, and a VUS may be reclassified over time as evidence accrues.

So a 23andMe carrier line means one detected founder variant, not disease. The situation that actually raises a future child’s risk is two carriers in a couple, which is exactly why partner testing is the decisive step. Because the home test reads only one spot, a negative result is weaker reassurance than a full SGCB sequencing panel. Only a physician and a board-certified genetic counselor combine genotype, creatine kinase, family history, and symptoms into a real diagnosis. That is why self-interpreting a home report in either direction is what a counseling visit prevents (NSGC.org).

Section recap: A carrier result is healthy, an affected diagnosis needs two variants plus symptoms, and a VUS is unresolved; only a clinician can interpret the full picture.

Prevention and management: family planning and neuromuscular care

Once a child inherits two broken SGCB copies, the disease itself cannot be prevented, so “prevention” works at the family-planning level. For couples where both partners are carriers, a genetic counselor can explain the reproductive options:

• Prenatal diagnosis: chorionic villus sampling or amniocentesis during pregnancy
• Preimplantation genetic testing (PGT) with IVF: testing embryos for the single-gene disease before transfer

Each option has trade-offs, and a counselor helps a couple weigh them.

Management for an affected person is different from prevention. Care is multidisciplinary supportive management, coordinated through a neuromuscular center. Physical therapy and stretching help preserve range of motion, and assistive devices support mobility as weakness progresses.

Two forms of monitoring deserve special attention, and standard care adds two more:

• Cardiac surveillance: echocardiography and ECG, because sarcoglycanopathy can affect the heart
• Respiratory monitoring: pulmonary function testing and breathing support when needed
• Orthopedic monitoring: watching for contractures
• Safe anesthesia planning: coordinated before any procedure

A large cohort confirmed that heart and breathing involvement occur in a subset of patients and warrant surveillance.

The practical takeaway is like scheduling regular maintenance on a car before a warning light appears. Early diagnosis and referral to a neuromuscular specialty center is the “early detection” that most improves quality of life. It anticipates heart and lung complications before they become emergencies. A genetic counselor or neurologist can point you to the right center (NSGC.org).

Section recap: LGMD2E cannot be undone once inherited, so prevention is reproductive; affected patients need multidisciplinary care with proactive cardiac and respiratory surveillance.

The treatment frontier: SRP-9003 gene therapy is investigational, not approved

Let us be plain about where treatment stands. As of this article’s date, there is no approved disease-modifying or gene-replacement therapy for LGMD2E that is FDA-approved or Health Canada-approved. Approved care remains supportive and multidisciplinary. Any headline suggesting a cure is available today is inaccurate.

That said, the research is genuinely promising and closely watched. The lead story is a gene-replacement therapy called bidridistrogene xeboparvovec, known as SRP-9003. It uses an AAVrh74 viral carrier to deliver a working copy of the SGCB gene, switched on by a muscle-specific promoter. In plain terms, it aims to give muscle cells the instructions they are missing.

The Phase 1/2 trial results were published in Nature Medicine in 2024. Key reported findings:

• Participants: children aged 4 to 15 with two SGCB mutations, each given a single infusion
• Day 60 result: the higher-dose group showed beta-sarcoglycan expression averaging about 62% of normal levels
• Durability: a later exploratory analysis reported preliminary motor improvements maintained through Year 2
• Most common side effects: vomiting and a rise in a liver enzyme
• Status: the therapy remained investigational throughout

The pivotal Phase 3 trial, called EMERGENE, is the next step. It is an open-label study of SRP-9003 in people aged 4 and older with beta-sarcoglycan deficiency, with beta-sarcoglycan expression at Day 60 as its main measure. The company announced that enrollment and dosing were completed on December 18, 2024, and a regulatory filing was publicly targeted.

Here is the honest bottom line, repeated on purpose. SRP-9003 is investigational and has not received FDA or Health Canada approval. It is not yet a prescribable treatment, and access is limited to trial participation. AAV gene therapies also carry class-related safety questions, such as immune responses and liver effects, that are still being evaluated. So the honest summary is that LGMD2E has moved from an untreatable disease toward a plausible molecular fix, without being approved yet. A neuromuscular specialist can tell you whether a trial is an option for a specific patient.

Section recap: There is no approved gene therapy for LGMD2E; SRP-9003 showed encouraging 2024 Phase 1/2 results and is in Phase 3, but it remains investigational and unapproved.

Family implications: cascade testing across relatives

A carrier or affected result rarely stays with one person. Both parents of an affected child are obligate carriers, and because the c.461C>G founder variant clusters in Amish and Pennsylvania Dutch-descended families, a result ripples across the family tree. Relatives who share that ancestry have a higher-than-average chance of carrying the same variant.

This is where cascade testing comes in. Cascade testing means offering targeted SGCB variant testing to a carrier’s siblings, cousins, and other at-risk relatives. They can then learn their own status before or during their own family planning. Each sibling of a carrier has roughly a 50% chance of also being a carrier. Learning this early gives relatives time to make informed choices.

For a couple where both are carriers, a genetic counselor can lay out the full menu of reproductive options:

• Natural conception with prenatal diagnosis — CVS or amniocentesis during pregnancy
• Preimplantation testing with IVF — screening embryos before transfer
• Donor gametes — using donor egg or sperm without the variant
• Accepting the 25% risk — with informed monitoring and early surveillance of any affected child

The best next step is a professional, not a search engine. Readers can find a board-certified genetic counselor through the NSGC “Find a Genetic Counselor” tool in the US (NSGC.org), or through provincial and territorial genetics clinics in Canada. Some community programs serving Plain communities may also offer targeted, lower-cost founder-variant testing.

Section recap: A carrier result matters for the wider family; cascade testing offers relatives their own answers, and each sibling of a carrier has about a 50% chance of also being a carrier.

Psychosocial and practical impact: GINA, insurance, and disclosure in the US and Canada

Seeing a “muscular dystrophy” carrier line attached to your own name carries real emotional weight, and many readers worry it will follow them. It is worth naming that carrier status itself carries no health consequence for the carrier, and informed partner testing usually resolves the central worry.

The insurance questions have clear answers, but the protections differ sharply between the two countries:

Protection	United States (GINA, 2008)	Canada (GNDA, 2017)
Health insurance	Protected	Protected
Employment	Protected	Protected
Life insurance	Not covered	Protected
Disability insurance	Not covered	Protected
Long-term-care insurance	Not covered	Protected

In the US, the Genetic Information Nondiscrimination Act (GINA, 2008) prohibits health insurers and employers from using genetic information to discriminate. The Affordable Care Act adds that health plans cannot deny or price coverage based on pre-existing conditions. But GINA does not cover life insurance, disability insurance, or long-term-care insurance, which is a real gap that carrier and affected families should understand before buying those policies. Canada offers broader protection: the Genetic Non-Discrimination Act (2017), upheld by the Supreme Court of Canada in 2020, extends protection across insurance and the provision of goods and services. So the map differs by country, and this is exactly the kind of detail a genetic counselor can help you plan around.

Coverage of care is generally reassuring, with caveats. Carrier screening and specialist neuromuscular, cardiac, and respiratory care are generally covered by US plans and by provincial health plans in Canada. But coverage of IVF with preimplantation testing, and of any future high-cost gene therapy, varies widely by state, province, and plan. It would be a live access question if SRP-9003 is ever approved. It is also normal to feel the emotional pull of a carrier line, to worry about existing children, and to wrestle with whether to tell relatives. A genetic counselor supports both the medical and the emotional side (NSGC.org).

Section recap: GINA protects US health insurance and employment but not life insurance; Canada’s law is broader, and a carrier line carries no health consequence for the carrier.

Frequently asked questions

Will I get the disease if my 23andMe report says I’m an LGMD2E carrier? No. LGMD2E is autosomal recessive, so a carrier with one broken SGCB copy and one working copy is healthy and will stay healthy. A carrier result matters only for family planning, not for your own muscle health. It is not a diagnosis.

Will my children inherit it? It depends entirely on your partner. If only you carry a variant and your partner tests negative, the practical risk to a child is very low. It is not mathematically zero, though, because the home test reads only one variant. If both partners are carriers, the chance is 25%, or about 25 out of 100 pregnancies. Partner carrier screening is the decisive next step.

Will this affect my health or life insurance? In the US, GINA blocks health insurers and employers from using genetic information, but it does not cover life, disability, or long-term-care insurance. In Canada, the Genetic Non-Discrimination Act, upheld by the Supreme Court in 2020, provides broader protection. Consider this gap before buying life or disability policies, and ask a genetic counselor.

Can my employer find out? In the US, GINA prohibits employers from using genetic information to make employment decisions. A carrier result is not a disease and has no bearing on your ability to work. A genetic counselor can explain your specific protections (NSGC.org).

Should I get a second opinion or confirmatory testing? Yes, if you want firmer answers, because a home test reads only one founder variant. A neurologist and a board-certified genetic counselor can order comprehensive SGCB testing and interpret it alongside your family history and any symptoms. Self-interpreting a home report is exactly what a counseling visit prevents.

Summary

A 23andMe carrier line for LGMD2E is reassuring at the personal level: because the disease is autosomal recessive, a carrier is healthy and stays healthy. The gene involved, SGCB, makes beta-sarcoglycan, a protein that helps shield muscle fibers, and losing it destabilizes the whole sarcoglycan team. The home test reads only the single Amish founder variant, so a negative result is only partial reassurance and does not replace clinical screening.

Real risk to a future child rises only if both partners are carriers, when the per-pregnancy chance is about 25 out of 100. Partner carrier screening is therefore the single pivotal next step, and cascade testing extends the same clarity to relatives. Affected patients need multidisciplinary care with proactive cardiac and respiratory surveillance. And while the gene therapy SRP-9003 reported encouraging Phase 1/2 results in 2024 and is now in Phase 3, it remains investigational and not FDA- or Health Canada-approved. For every step, a physician and a board-certified genetic counselor turn this information into a plan (NSGC.org).

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Mendell JR, Pozsgai ER, Lewis S, et al. (2024). Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/38177855/
2. NIH MedlinePlus Genetics. SGCB gene. https://medlineplus.gov/genetics/gene/sgcb/
3. NIH MedlinePlus Genetics. Limb-girdle muscular dystrophy. https://medlineplus.gov/genetics/condition/limb-girdle-muscular-dystrophy/
4. OMIM #604286. Muscular Dystrophy, Limb-Girdle, Autosomal Recessive 4 (LGMDR4/LGMD2E). https://omim.org/entry/604286
5. Bönnemann CG, Modi R, Noguchi S, et al. (1995). Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genetics. https://www.nature.com/articles/ng1195-266
6. NHGRI / genome.gov. Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA, 2008). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
7. FDA. De Novo authorization — 23andMe Personal Genome Service Carrier Status reports. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm
8. ClinicalTrials.gov. EMERGENE (Study SRP-9003-301) — bidridistrogene xeboparvovec in LGMD2E/R4 (NCT06246513). https://clinicaltrials.gov/study/NCT06246513
9. Straub V, Murphy A, Udd B, et al. (2018). 229th ENMC international workshop: Limb girdle muscular dystrophies — nomenclature and reformed classification. Neuromuscular Disorders 28(8):702-710. https://pubmed.ncbi.nlm.nih.gov/30055862/
10. Alonso-Pérez J, González-Quereda L, Bello L, et al. (2020). New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain. https://pubmed.ncbi.nlm.nih.gov/32483488/
11. Richards S, Aziz N, Bale S, et al. (2015). Standards and guidelines for the interpretation of sequence variants (ACMG/AMP). Genetics in Medicine 17(5):405-424. https://pubmed.ncbi.nlm.nih.gov/25741868/
12. Gregg AR, Aarabi M, Klugman S, et al. (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: an ACMG practice resource. Genetics in Medicine 23(10):1793-1806. https://pubmed.ncbi.nlm.nih.gov/34285390/
13. NORD (National Organization for Rare Disorders). Limb-Girdle Muscular Dystrophy. https://rarediseases.org/rare-diseases/limb-girdle-muscular-dystrophy/
14. Sarcoglycanopathy epidemiology and the SGCB c.461C>G (p.Thr151Arg) Old Order Amish founder-variant literature. https://pubmed.ncbi.nlm.nih.gov/17994539/

---

Last updated: 2026-08-17

Author: genelumen editorial team. This article aggregates 14 sources from peer-reviewed medical literature and public health agencies (tier 1=8 / tier 2=6), including NIH MedlinePlus, OMIM, GeneReviews (NCBI), the FDA, ClinicalTrials.gov, ACMG guidelines, and NORD.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Neurogenetic Diseases category

🌐 日本語版: https://genelumen.com/ja/ja-neurogenetic/lgmd-2e-sgcb-carrier-inheritance-guide-ja